Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WVE 10.01.2024

Full Press ReleaseSEC FilingsOur WVE Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
  • 12.23.2024 - Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

CAMBRIDGE, Mass.,Oct. 01, 2024(GLOBE NEWSWIRE) --Wave Life Sciences Ltd.(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today that it closed its previously announced underwritten public offering, and that the underwriters exercised in full their option to purchase an additional 3,750,000 of its ordinary shares at the public offering price of$8.00per ordinary share, less underwriting discounts and commissions. After giving effect to the full exercise of the underwriters’ option to purchase additional shares, the total number of ordinary shares sold in the offering is 26,875,001 ordinary shares which, along with the sale of pre-funded warrants to purchase 1,875,023 ordinary shares, resulted in aggregate gross proceeds toWave Life Sciencesof approximately$230 million, before deducting underwriting discounts and commissions and offering expenses.

J.P. Morgan andLeerink Partnersacted as joint book-running managers for the offering. Truist Securities and Mizuho acted as book-runners for the offering.

The offering was made only by means of a prospectus and related prospectus supplement forming part of a shelf registration statement that was previously filed with and declared effective by theSecurities and Exchange Commission(“SEC”). The final prospectus supplement and accompanying base prospectus relating to the offering were filed with theSEConSeptember 27, 2024and are available on the SEC’s website located athttp://www.sec.gov, copies of which may be obtained fromJ.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue,Edgewood, NY11717, or by email atprospectus-eq_fi@jpmchase.comandpostsalemanualrequests@broadridge.com; or fromLeerink Partners LLC,Syndicate Department,53 State Street, 40th Floor,Boston, MA02109, or by telephone at (800) 808-7525, ext. 6105, or by email atsyndicate@leerink.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

AboutWave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected and Wave cautions investors not to place undue reliance on the forward-looking statements in this press release. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s final prospectus supplement related to the offering filed with theSEConSeptember 27, 2024and Wave’s most recent Annual Report on Form 10-K filed with theSEC, as amended, and in other filings Wave makes with theSECfrom time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Investor Contact:Kate Rausch+1 617-949-4827krausch@wavelifesci.com

Media Contact:Alicia Suter+1 617-949-4817asuter@wavelifesci.com

Primary Logo

Source: Wave Life Sciences USA, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com